StockNews downgraded EyePoint Pharmaceuticals (NASDAQ:EYPT) from a hold to a sell rating.
StockNews downgraded EyePoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a sell rating. Despite the downgrade, analysts maintain a consensus rating of "Buy" with an average 1-year target price of $34.14. Recent analyst actions include HC Wainwright decreasing their target price to $33, Mizuho lowering it to $30, and JPMorgan Chase starting coverage with an "overweight" rating and $35 target price.
May 12, 2024
3 Articles